TSE.4540

Supplementary Materials

The First Quarter of the Term Ending March 31, 2024

August 3, 2023

TSUMURA & CO.

Consolidated Statements of Income ・・・・・

1

investments, R&D expenses, etc. ・・・・・

1

Product sales

・・・・・

2

Growth rates of 129 prescription Kampo products ・・・・・

2

Consolidated Balance Sheets

・・・・・

3

Consolidated Statements of Cash Flows ・・・・・

3

Quarterly data

Consolidated Statements of Income ・・・・・

4

Consolidated Balance Sheets

・・・・・

4

Consolidated Statements of Cash Flows ・・・・・

5

Product sales

・・・・・

5

Consolidated Statements of Income

(Million yen)

FY 3/2023 1Q

FY 3/2024 1Q

Year-on-year

Forecast for 2Q (cumulative total)

Full-year forecast for FY 3/2024

Year-on-

Year-on-year

Year-on-

Year-on-

Amount

% of sales

Amount

% of sales

Amount

%

Amount

% of sales

year

Amount

% of sales

year

year

(Amount)

(%)

(Amount)

(%)

Net sales

34,417

100.0%

37,036

100.0%

2,618

7.6%

74,000

100.0%

3,892

5.6%

150,500

100.0%

10,456

7.5%

Domestic business

31,562

92.9%

32,988

89.1%

1,426

4.5%

65,900

89.1%

2,985

4.7%

133,300

88.6%

8,601

6.9%

China business

2,855

7.1%

4,047

10.9%

1,191

41.7%

8,100

10.9%

906

12.6%

17,200

11.4%

1,854

12.1%

Cost of sales

16,462

47.8%

20,341

54.9%

3,879

23.6%

39,600

53.5%

4,302

12.2%

83,000

55.1%

11,237

15.7%

Gross profit on sales

17,954

52.2%

16,694

45.1%

(1,260)

(7.0)%

34,400

46.5%

(409)

(1.2)%

67,500

44.9%

(781)

(1.1)%

Selling, general and administrative expenses

11,601

33.7%

12,009

32.4%

408

3.5%

24,900

33.6%

1,767

7.6%

49,500

32.9%

2,134

4.5%

Operating profit

6,353

18.5%

4,684

12.6%

(1,668)

(26.3)%

9,500

12.8%

(2,177)

(18.6)%

18,000

12.0%

(2,916)

(13.9)%

Domestic business

6,404

18.6%

4,684

ー

(1,719)

(26.9)%

9,900

ー

(1,865)

(15.9)%

18,400

ー

(2,790)

(13.2)%

China business

(50)

(0.1)%

0

ー

51

ー

(400)

ー

(312)

ー

(400)

ー

(126)

ー

Ordinary profit

8,665

25.2%

5,989

16.2%

(2,676)

(30.9)%

9,800

13.2%

(6,165)

(38.6)%

18,600

12.4%

(4,853)

(20.7)%

Profit attributable to owners of parent

6,632

19.3%

4,332

11.7%

(2,300)

(34.7)%

6,800

9.2%

(5,089)

(42.8)%

13,000

8.6%

(3,482)

(21.1)%

Investments, R&D expenses, etc.

(Million yen)

FY 3/2023 1Q

FY 3/2024 1Q

Year-on-year

Forecast for 2Q (cumulative total)

Full-year forecast for FY 3/2024

Year-on-

Year-on-year

Year-on-

Year-on-

Amount

% of sales

Amount

% of sales

Amount

%

Amount

% of sales

year

Amount

% of sales

year

year

(Amount)

(%)

(Amount)

(%)

Investments

2,251

6.5%

3,889

10.5%

1,637

72.7%

11,000

14.9%

4,265

63.3%

33,500

22.3%

18,820

128.2%

Capital investments

2,037

5.9%

2,660

7.2%

623

30.6%

9,500

12.8%

4,748

100.0%

29,500

19.6%

18,327

164.0%

R&D expenses

2,139

6.2%

2,218

6.0%

79

3.7%

4,400

5.9%

734

20.0%

8,500

5.6%

905

11.9%

Advertising expenses

126

0.4%

105

0.3%

(20)

(16.4)%

400

0.5%

(7)

(1.8)%

1,000

0.7%

(26)

(2.6)%

Depreciation

2,456

7.1%

2,454

6.6%

(1)

(0.1)%

4,900

6.6%

(80)

(1.6)%

10,200

6.8%

98

1.0%

Personnel expenses

8,355

24.3%

8,898

24.0%

542

6.5%

18,500

25.0%

1,641

9.7%

36,800

24.5%

2,555

7.5%

1

Product sales

(Million yen)

Rank

No.

Product Name

FY 3/2023

FY 3/2024

Year-on-

Year-on-

1Q

1Q

year

year

1

☆

100

Daikenchuto

2,505

2,515

9

0.4%

2

☆

54

Yokukansan

1,933

1,940

6

0.4%

3

G

41

Hochuekkito

1,881

1,931

49

2.6%

4

☆

43

Rikkunshito

1,860

1,861

1

0.1%

5

G

17

Goreisan

1,542

1,801

259

16.8%

6

G

24

Kamishoyosan

1,296

1,305

9

0.7%

7

68

Shakuyakukanzoto

1,281

1,043

(238)

(18.6)%

8

62

Bofutsusyosan

794

1,001

206

26.0%

9

☆

107

Goshajinkigan

932

995

62

6.7%

10

29

Bakumondoto

805

878

72

9.0%

17

G

137

Kamikihito

501

590

88

17.7%

18

G

108

Ningin'yoeito

507

561

54

10.6%

23

☆

14

Hangeshashinto

359

370

11

3.2%

Total of "Drug Fostering" Program formulations

7,591

7,683

92

1.2%

Total of Growing formulations

5,730

6,191

461

8.0%

Total of 129 prescription Kampo products

30,277

31,838

1,560

5.2%

☆ ："Drug Fostering" Program formulations

G：Growing formulations

Growth rates of 129 prescription Kampo products

FY 3/2019

FY 3/2020

FY 3/2021

FY 3/2022

FY 3/2023

FY 3/2024

1Q

Amount

2.7%

1.8%

1.1%

8.1%

4.6%

5.2%

Number of items with higher yen sales

83

66

82

110

98

90

2

Consolidated Balance Sheets

(Million yen)

As of March 31

As of June 30

Increase /

2023

2023

decrease

Total assets

396,813

405,437

8,623

Current assets

268,320

272,369

4,048

Liquid assets

152,839

150,589

(2,250)

Inventories

101,726

107,501

5,774

Non-current assets

128,492

133,067

4,574

Property, plant and equipment

93,415

94,530

1,114

Total liabilities

124,566

126,345

1,779

Current liabilities

47,205

49,402

2,197

Non-current liabilities

77,361

76,943

(418)

Total net assets

272,246

279,091

6,844

Consolidated Statements of Cash Flows

(Million yen)

FY 3/2023

FY 3/2024

Year-on-year

1Q

1Q

Cash flows from operating activities

4,785

(152)

(4,937)

Cash flows from investing activities

(4,145)

(4,906)

(760)

Cash flows from financing activities

(2,418)

(1,579)

839

Cash and cash equivalents at the end of the quarter

68,022

88,917

20,894

3

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Tsumura & Co. published this content on 03 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 August 2023 07:31:20 UTC.